Roche has lost its top spot in 2010 as the most efficient R&D company after 5 years. It had its failures and 2 BLA/NDA rejections by the FDA. Avastin failure in breast cancer may be made up by positive Phase III in other cancer.
A live updated review of new drug approvals, rejections and market withdrawals by the FDA and EMA in the year 2010 is provided. Safety issues derailed the approval of several new drugs, withdrawal of Meridia (Abbott) and Avandia (in Europe, restricted in the US). Pfizer had 3 new drugs approved by the FDA. Lilly R&D had a poor year with 3 Phase III failures and a BLA rejection. Roche, Novartis and Astra Zeneca each had 2 BLA/NDA rejected by the FDA and its advisory panel.